Media headlines about Sinovac Biotech (NASDAQ:SVA) have trended somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sinovac Biotech earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.6401529723489 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Sinovac Biotech (NASDAQ SVA) traded up $0.07 during mid-day trading on Tuesday, hitting $8.34. The company had a trading volume of 19,121 shares, compared to its average volume of 74,350. Sinovac Biotech has a 1-year low of $4.60 and a 1-year high of $8.67. The company has a market cap of $465.56, a P/E ratio of -831.17 and a beta of 0.19.
Separately, BidaskClub downgraded Sinovac Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th.
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.